Physician profile
Jeffrey M Joseph
NPI 1134395205
$292,264.70
in general payments reported to CMS, 2019-2025
7 companies · $7,600 in 2025
The $7,600 reported for 2025 was more than what 88% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $11K · 2021: $16K · 2022: $126K · 2023: $63K · 2024: $68K · 2025: $7,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Consulting Fee: $42K · Travel and Lodging: $19K · Food and Beverage: $5,106 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,875.00 |
| Consulting Fee | $42,483.33 |
| Travel and Lodging | $18,938.34 |
| Food and Beverage | $5,105.98 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $152,587.55 | 2019-2022 | |
| Abbvie INC. | $118,824.07 | 2023-2025 | |
| Galderma Laboratories, L.P. | $20,538.73 | 2019-2024 | Dysport |
| Shire North American Group INC | $143.85 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $143.08 | 2024-2025 | Xdemvy |
| Helsinn Therapeutics (U.S.), INC. | $14.43 | 2020 | |
| Vyne Pharmaceuticals INC. | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.